Stockreport

Rigel Announces Publication of Data on REZLIDHIA® (Olutasidenib) in Post-Venetoclax Patients with Mutant IDH1 AML in Leukemia & Lymphoma [Yahoo! Finance]

Rigel Pharmaceuticals, Inc.  (RIGL) 
Last rigel pharmaceuticals, inc. earnings: 2/27 04:01 pm Check Earnings Report
US:NASDAQ Investor Relations: ir.rigel.com
PDF Safety was consistent with the overall profile of olutasidenib Olutasidenib may offer a valuable treatment option for patients with mIDH1 previously treated with vene [Read more]